- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01526889
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy
This was a multi-center, randomized, active-controlled, open-label study. Approximately 24 patients with active, non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy were enrolled.
Safety, efficacy, and PK assessments occurred at scheduled visits over a 12-week period. Low-molecular-weight non-steroidal immunosuppressive medications were allowed up to the baseline day as long as the dose had not changed in the 3 weeks prior to baseline, except for corticosteroid doses for which might have changed.
Patients responding to treatment were offered up to 6 months of extended treatment. Assessments for safety included laboratory safety tests, ECGs, physical exams, ocular exams, vital signs and the monitoring of adverse events. Study participation varied from a minimum of 3 months to a maximum of 9 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 24 patients with active non-infectious uveitis, in at least one eye, requiring intensification of systemic immunosuppressive therapy were enrolled and randomized to receive intravitreal LFG316 or conventional therapy (investigator's discretion). Only one eye (the study eye) were treated with LFG316 and the other eye (fellow eye) were treated at the investigator's discretion.Throughout the study, the fellow eye might have been treated as needed; except that certain systemic medications were prohibited. There was 1 screening and 8 scheduled visits over 85 days for a total of 9 site visits for all patients.
At Day 85, patients receiving LFG316 treatment who met the criteria for a 'responder', were offered an additional 6 months of LFG316 treatment on a PRN basis. Additional 3 scheduled visits were attended by LFG316-responder patients during the extension period. However, patients could have unscheduled visits as needed and as determined by the investigator. Safety evaluation and ocular assessments were performed throughout the study duration. Patients in the treatment extension phase, who experienced a flare post their last dose and required treatment, might have received a dose of LFG316. These patients were assessed for a response at their next PRN visit as scheduled by the investigator. Visit frequency was determined by the investigator. If they continued to respond to LFG316 therapy, they might have remained in the PRN treatment arm. They might have received up to 7 additional doses of LFG316 in the PRN period. Throughout the trial LFG316 were not administered more frequently than monthly. Patients in the extension phase, who discontinued treatment prematurely were asked to return approximately 1 month after their last dose. Low molecular weight non-steroidal immunosuppressive medications were allowed up to the baseline day as long as the dose had not changed in the 3 weeks prior to baseline, except for corticosteroid doses which might have changed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bristol, United Kingdom, BS1 2LX
- Novartis Investigative Site
-
London, United Kingdom, EC1V 2PD
- Novartis Investigative Site
-
-
-
-
Colorado
-
Golden, Colorado, United States, 80401
- Novartis Investigative Site
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Novartis Investigative Site
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02142
- Novartis Investigative Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198-5540
- Novartis Investigative Site
-
-
New Jersey
-
Teaneck, New Jersey, United States, 07666
- Novartis Investigative Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Male or female patients 18 years or older
- Active NIU, in at least one eye, as defined below, in patients requiring intensification of systemic immunosuppressive therapy;
- Vitreous haze at least 1+ on the scale of Nussenblatt et al 1985,or
- Chorioretinal lesions due to uveitis (chorioretinal lesions due to infectious uveitis excluded)
- Patients with a flare and at the time of the enrollment on systemic corticosteroid or non-steroidal immunosuppressants had their therapy tapered or stopped, respectively, at the time of intravitreal LFG316 administration.
Visual acuity (ETDRS method) of 20 letters (20/400 Snellen equivalent) or better in the study eye.
- For female patients, must not be pregnant or lactating and must, unless post-menopausal, use effective contraception.
- Ability to provide informed consent and comply with the protocol.
Key Exclusion Criteria:
- Uveitis so severe that, in the investigator's judgment, it was too risky to test an experimental drug
- Any biologic immunosuppressive agent given via intravitreal, intravenous or subcutaneous route within 4-12 months depending on the agent.
- History of infectious uveitis or endophthalmitis in either eye.
- History of retinal detachment
- Any intraocular surgery, intravitreal injection, periocular injection, or laser photocoagulation to the study eye within 90 days prior to dosing.
- In the study eye, cataract expected to interfere with study conduct or require surgery during the study.
- Forms of uveitis that may have spontaneously resolved
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LFG316 -Intravitreal Injection
|
LFG316 administered intravitreally (IVT)
|
ACTIVE_COMPARATOR: Conventional Therapy
|
Conventional Therapy administered in accordance with its prescribing info.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Response Rate for the Individual Response Criteria - in the Study Eye
Time Frame: Day 85 (end of study)
|
Response rate as defined by:
|
Day 85 (end of study)
|
Number of Participants With Remission in Study Eye - Treatment Period
Time Frame: Day 85 (end of study)
|
Remission (complete response) was defined as any patient who had:
|
Day 85 (end of study)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Vitreous Haze Score in Study Eye - Treatment Period
Time Frame: Day 2, 8, 15, 29, 43, 57 and, 85 (end of the study)
|
Vitreous haze score (based on funduscopic exam): 0, 0.5/Trace, 1+, 2+, 3+, 4+ Vitreous haze score (scale of 0 to 4) with a score of 4 being the most hazed. |
Day 2, 8, 15, 29, 43, 57 and, 85 (end of the study)
|
Mean Best Corrected Visual Acuity (BCVA) in Study Eye - Treatment Period
Time Frame: Day 2, 8, 15, 29, 43, 57 and, 85 (end of the study)
|
Visual acuity was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) eye charts under ETDRS conditions. ETDRS best-corrected visual acuity was obtained in each eye separately under certified ETDRS conditions. This assessment was to be performed prior to pupil dilation. The number of letters read correctly (for each eye) was recorded. BCVA is based on the number of letters read correctly. |
Day 2, 8, 15, 29, 43, 57 and, 85 (end of the study)
|
Number of Patients With Macular Edema in Study Eye - Treatment Period
Time Frame: Day 85 (end of study)
|
Macular edema is a sign of uveitis.
|
Day 85 (end of study)
|
Number of Patients With Chorioretinal Lesions in Study Eye - Treatment Period
Time Frame: Day 2, 8, 15, 29, 43, 57 and, 85 (end of the study)
|
Chorioretinal lesions is a sign of uveitis.
|
Day 2, 8, 15, 29, 43, 57 and, 85 (end of the study)
|
Number of Participants With Anterior Chamber Cells Score in Study Eye - Treatment Period
Time Frame: Day 2, 8, 15, 29, 43, 57 and, 85 (end of the study)
|
anterior chamber cells score (ACCS) with the scores being 0 (≤ 1 cell), 0.5 (1 to 5 aqueous cells), 1 (6 to 15 aqueous cells), 2 (16 to 25 aqueous cells), 3 (26 to 50 aqueous cells), 4 (>50 aqueous cells).
|
Day 2, 8, 15, 29, 43, 57 and, 85 (end of the study)
|
Number of Participants With or Without Anti-LFG316 Antibodies
Time Frame: Throughout the study (treatment and extension period), up to day 271
|
Blood will be collected at each visit for the profiling of serum drug concentrations. The summary of immunogenicity (IG) by visit . The immunogenicity data (presence/absence of anti-LFG316 antibodies [anti-drug antibodies]). NO: No immunogenicity; YES: Positive immunogenicity. |
Throughout the study (treatment and extension period), up to day 271
|
Mean Percent Change in Total C5 Concentrations in Serum - Treatment Period
Time Frame: Day 2, 15, 29, 43, 57 and, 85 (end of the study)
|
Percent change from baseline (using each patient's pre-dose value as baseline) in total C5 concentrations.
|
Day 2, 15, 29, 43, 57 and, 85 (end of the study)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLFG316A2204
- 2011-003254-90 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-infectious Intermediate Uveitis
-
Priovant Therapeutics, Inc.Active, not recruitingNon-infectious Intermediate Uveitis | Non-infectious Posterior Uveitis | Non-infectious Pan UveitisUnited States
-
AbbVieActive, not recruitingNon-infectious Intermediate Posterior- or Pan-uveitisChina
-
National Eye Institute (NEI)CompletedNon-infectious Intermediate and Posterior UveitisUnited States
-
Alumis IncActive, not recruitingUveitis, Intermediate | Noninfectious Panuveitis | Uveitis Posterior Non-InfectiousUnited States
-
AbbVieCompletedNon-infectious Intermediate, Posterior and PanuveitisKorea, Republic of
-
National Eye Institute (NEI)TerminatedNon-infectious Intermediate and Posterior UveitisUnited States
-
EyePoint Pharmaceuticals, Inc.CompletedPanuveitis | Posterior Uveitis | Intermediate UveitisIndia
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
University of NebraskaUnknownPosterior Uveitis | Intermediate Uveitis | Pan-uveitisUnited States
-
Duke UniversityCompletedPosterior Uveitis | Intermediate UveitisUnited States
Clinical Trials on LFG316
-
Novartis PharmaceuticalsTerminatedNeovascular Age-related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedAge-related Macular Degeneration | Geographic AtrophyUnited States
-
Novartis PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria PNHLithuania, Japan, Czechia
-
Novartis PharmaceuticalsTerminatedTransplant Associated Microangiopathy TAMFrance, United States, Germany
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedExudative Macular Degeneration | Neovascular Age-elated Macular Degeneration (Wet AMD)United States
-
Alcon ResearchNovartis Institutes for BioMedical ResearchCompleted
-
Novartis PharmaceuticalsCompletedAdvanced Age-related Macular DegenerationUnited States